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Abstract. About 95% of cases and 98% of deaths due to tuberculosis (TB) occur in tropical 
countries while, in temperate low incidence countries, a disproportionate portion of TB cases is 
diagnosed in immigrants.  
Urbanization, poverty, poor housing conditions and ventilation, poor nutritional status, low 
education level, the HIV co-epidemic, the growing impact of chronic conditions such as diabetes are 
the main determinants of the current TB epidemiology in tropical areas. TB care in these contests is 
complicated by several barriers such as geographical accessibility, educational, cultural, 
sociopsychological and gender issues. High quality microbiological and radiological facilities are 
not widely available, and erratic supply of anti-TB drugs may affect tropical areas from time to 
time. Nevertheless in recent years, TB control programs reached major achievements in tropical 
countries as demonstrated by several indicators.  
Migrants have a high risk of acquire TB before migration. Moreover, after migration, they are 
exposed to additional risk factors for acquiring or reactivating TB infection, such as poverty, 
stressful living conditions, social inequalities, overcrowded housing, malnutrition, substance abuse, 
and limited access to health care. TB mass screening programs for migrants have been 
implemented in low endemic countries but present several limitations. Screening programs should 
not represent a stand-alone intervention, but a component of a wider approach integrated with 
other healthcare activities to ensure the health of migrants. 
Introduction. Despite encouraging progress, the 
burden of tuberculosis (TB) remains enormous with 
about one third of the World population latently 
infected with the etiologic agent Mycobacterium 
tuberculosis,
1
 8.7 million new cases of active disease 
and 1.4 million people died in 2011.
2
 Some authors 
state that 95% of all cases and 98% of deaths due to 
TB, occurs in tropical countries.
3
 In the matter of facts 
among the 22 high burden countries that account for 
more than 80% of the worldwide incident cases of the 
disease, 19 have territories geographically located, at 
least in part, within the tropics (Table 1), indicating 
tropical areas as the most affected by TB in the World. 
In high income industrialized countries, the majority of  
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Table 1. High burden countries with territories located within the tropics and estimated incidence.2 
High burden country in the tropics 
Estimated incidence 
(rate per 100,000 population) 
Estimated number of cases 
(number in thousands) 
Estimated portion respect 
to the global burden 
Bangladesh 225 340 4% 
Brazil 42 83 1% 
Cambodia 424 61 0.7% 
China 75 1000 11.5% 
Democratic Republic of the Congo 327 220 2.5% 
Ethiopia 258 220 2.5% 
India 181 2200 25% 
Indonesia 187 450 5.2% 
Kenya 288 120 1.4% 
Mozambique 548 130 1.5% 
Myanmar 381 180 2% 
Nigeria 118 190 2.2% 
Philippines 270 260 3% 
South Africa 993 500 5.7% 
Thailand 124 86 1% 
Uganda 193 67 0.8% 
United Republic of Tanzania 169 78 0.9% 
Viet Nam 199 180 2% 
Zimbabwe 603 77 0.9% 
Afghanistan, Pakistan and Russian Federation are considered high burden countries but they have not territories located within the tropics. 
 
which are located outside the tropics, the overall TB 
incidence is low, as expected given the inverse 
correlation between economic development of the 
country and its TB diffusion.
4
 A disproportionate and 
growing portion of subjects affected by TB in 
industrialized countries are migrants from tropical 
countries,
5,6
 configuring this group of subjects as a TB 
vulnerable population in low endemic areas.  
The aim of this review is to give an overview on the 
historical, epidemiological, clinical and 
microbiological characteristics and recent control 
strategies of TB in tropical countries and migrant 
populations. 
 
History of TB in Tropical Areas and Migration. 
Current evidence supports the so called "Out-of-and-
back-to-Africa" scenario in explaining the origin and 
global spread of human TB.
7
 Human M. tuberculosis 
complex probably originated in Africa and 
accompanied the Out-of-Africa migrations of modern 
humans approximately 70,000 years ago.
7
 The three 
phylogenetically ‘modern’ lineages of M. tuberculosis 
complex (namely the East Asian, the Central 
Asian/Delhi and the Euro-American lineage) seeded in 
China, India and Europe, respectively where human 
population strongly grew during the last few centuries.
7
 
As overcrowding conditions and the urbanization 
increased, TB expanded in these areas and 
concomitantly spread globally through waves of human 
migrations.
7
 Through European colonization, the Euro-
American lineage of M. tuberculosis complex reached 
other regions such as the Americas in the mid 
nineteenth century and sub-Saharan Africa at the 
beginning of the twentieth century.
7,8
 Historians and 
paleopathologists, supported by the detection of 
mycobacterial DNA in pre-Columbian human remains, 
suggests that TB was already present in pre-Columbian 
America. Today most TB in the Americas is caused by 
the Euro-American lineage, but in the pre-Columbian 
period, the etiologic agent may have been Asian forms, 
as would be expected given the original human 
colonization of the Americas via the Bering Strait. 
Alternatively, pre-Columbian TB might have been 
caused by mycobacterial lineages which are now 
extinct perhaps because they were outcompeted by the 
Euro-American lineage following the massive influx of 
Europeans into the Americas between the early 
eighteenth and early twentieth century.
7
 
 
Epidemiology and Determinants of Tuberculosis in 
Tropical Areas. The majority of the known risk 
factors for acquiring TB infection and for progress to 
TB disease after the infection are widespread and 
responsible for the high burden of TB in tropical areas.  
About 59% of new estimated TB cases occur in 
South East Asia and the Western Pacific Regions,
2
 
where some of the most populated countries (India, 
China, Indonesia) and some of the most crowded cities 
of the World are located.
9
 Urbanization and the 
consequent overcrowded living conditions, through the 
increase of shared airspace between individuals, are 
among the well-known risk factors to acquire TB.
10 
 
Urbanization is a relatively new, but growing 
phenomenon in Africa, which is substantially less 
populated than Asian regions.
9
 However, countries of 
the African Region account for 26% of the World's TB 
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cases and they have the highest incidence rate of cases 
and death per capita.
2
 In Africa, the TB epidemic is 
overlapped and strongly driven by HIV infection which 
is the most powerful risk factor for developing active 
TB disease in subjects infected with M. tuberculosis.
11
 
In this region, 46% of subjects who develop active TB 
are estimated to be co-infected with HIV (ranging from 
8% in Ethiopia to 77% in Swaziland).
2
 In extreme 
settings, such as gold-mining workforce in South 
Africa, the annual incidence reaches value of 2,000-
3,000 per 100,000 population due to the high rate of 
HIV co-infection (up to 80% among subjects with 
active TB) and silicosis.
12
 
Concerning countries of the region of Americas, 
only Brazil, is considered a high burden country given 
its relevant contribution to the absolute number of TB 
cases, despite a relatively low overall incidence rate 
(less than 50 per 100,000 population). However, the 
burden of TB in Brazil is not uniformly distributed in 
the national territories with more 70% of cases 
concentrated in 315 over 5,564 municípios 
corresponding to those hosting the large metropolitan 
cities where overcrowding and extreme poverty is more 
frequent.
13
 In some districts of São Paolo (Brazil) 
where the Human Development Index is particularly 
low, TB incidence is 167 per 100,000 population.
14
 
Some tropical countries such as Haiti, Peru, Bolivia 
and Suriname have the highest incidence of TB in the 
Americas (between 100 and 200 per 100,000 
population).
15
 HIV co-epidemic is probably one of the 
most important determinant of the high incidence 
found in Sub-Saharan Africa, as well in Brazil and 
Haiti, where about 20% of incident TB cases is HIV 
co-infected.
15
 
Re-infection of subjects with previous latent 
tuberculosis infection (LTBI), which account for up to 
40% of the general population in countries like India,
16
 
may play an important role. Even if people with LTBI, 
have a markedly lower risk of developing TB disease 
after a re-infection if compared with previously 
uninfected subjects,
17
 in endemic areas the contribution 
of re-infection may account up to 70% of TB relapse 
cases.
18
 
A very important, even if distal, determinant of TB 
in tropical areas is poverty that affects housing 
conditions, ventilation, nutritional status, education and 
the access to health care system.
19
 In some areas of 
India, for example, the amount of monthly earning as 
well as the schooling degree have been correlated to 
TB prevalence.
19
 About two third of cases are 
diagnosed between 15-44 years of age in countries 
such as South Africa and India. The impact on the 
health status of young adults in their most 
economically active years makes that not only does 
poverty predispose one to TB, but also TB can increase 
poverty.
19
 In India three to four months of work time, 
the equivalent to 20–30 per cent of annual household 
income, are typically lost because of TB.
19
 
A growing role of emergent risk factors for 
progression from latent to active TB, such as certain 
chronic conditions, have been observed more recently 
in tropical areas. Smoking doubles the risk of TB and 
might account for up to half of all deaths in men with 
TB in India.
20
 Diabetes is associated with an about 
three-times increase in TB risk accounting for about 
20% of smear-positive tuberculosis cases in India in 
2000.
20
 Helminthic infestations that are endemic in 
tropical countries are strongly suspected to negatively 
impact on TB diseases inducing immunological 
alterations including alternatively activation of 
macrophages and Th1-lymphocytes response 
impairment.
21
 In a cohort of HIV-infected Ugandan 
adults, Schistosoma mansoni infestation was associated 
with an increased risk of TB progression.
22
 Finally, 
according to a recent review of the literature on racial 
difference in susceptibility to infection by M. 
tuberculosis, black skin people may have consistently 
higher susceptibility to TB if compared to whites skin 
peoples due to environmental, immunologic, and 
genetic factors.
23
 
 
Epidemiology and Determinants of Tuberculosis in 
Immigrants. TB is a well-known phenomenon linked 
to migration. By the time of the Italian migration to 
America between the XX and the XXI century, Italian 
migrants, resettled in New York city, worked in the 
factories of the metropolis in very poor housing and 
living conditions. In this setting, Italian migrants 
experienced a very high number of TB cases with tens 
of cases per household and the block where they lived 
was named “lung’s block”.24 
Today, migration is a global social phenomenon 
that may be defined as a movement of people within 
and among countries as a consequence of wealth 
disparity, poverty, wars, natural disasters and political 
persecution.
19,25
 To date there are an estimated 740 
million internal migrants and 200 million of 
international migrants (Figure 1),
26
 without 
considering irregular migrants of which it is difficult to 
make an affordable estimate.  
Many migrants originate from countries where TB 
have a high incidence, such as tropical countries, and 
resettle in higher income countries, such as Unites 
States, Canada, Australia, New Zealand and western 
Europe, where TB incidence is now very low (less than 
10 per 100,000 population) (Table 2).
25
 
In the United States (US), TB cases in foreign-born 
persons accounted for 62% of total TB cases in 2011 
with Asians accounting for 29% and Hispanics/Latinos 
for 21% of all cases.
6
 Considering the countries
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Figure 1. The pattern of inter- and intra-regional migrant movements. [United Nations Development Programme, Summary. Human 
Development Report 2009. Overcoming barriers: Human mobility and development, United Nations Development Program, (2009). 
Reproduced with permission] 
 
belonging to the European Economic Area (EEA), 
foreign origin persons represented 26% of cases 
diagnosed in 2011.
5
 However, this percentage rises to 
more than 40% in the western European countries  
holding the highest proportions of migrants in Europe 
(Table 2).
5
 In the EEA the majority of foreign origin 
subjects diagnosed with TB in 2009 originated from 
Asia (34.2%), Africa (28.6%) and other European 
countries (19.9%).
27
 
Immigration is playing an important role in the 
epidemiology of TB in certain high burden countries 
with emerging economies. In some districts of São 
Paolo (Brazil), the portion of TB cases diagnosed in 
Bolivian migrants grew up to 53% of total cases in the 
period 1998-2008,
14
 while migrant workers from rural 
areas of China resettled in the district of Shanghai 
accounted for 67.4% of cases diagnosed in 2006-
2008.
28
 
It is clear that migrants currently play an important 
role in determining the current epidemiology of TB in 
countries where they settled. However reports from 
different high income countries with well-performing 
screening and treatment systems have shown that 
foreign-born TB patients do not contribute importantly 
to TB transmission in the native population.
25,29,30
 
Based on genotyping analysis, a variable portion of TB 
cases in native populations (ranging from 2% to 17%) 
has been attributed to transmission from foreign-born 
subjects.
31,32
 In more recent study, performed in 
Denmark, transmission from Danes to migrants 
occurred 2.5 times more frequently than vice-versa.
30
 
Migrants are exposed in their country of origin to 
several risk factors for TB infection and progression as 
already explained in the above paragraph.  
The incidence in the countries of origin is the 
strongest predictor of TB incidence in migrants 
according to some authors.
33
 However in other studies 
the TB incidence in selected migrant communities was 
found to be lower or higher if compared with the 
incidence in the country of origin according to the 
degree of socio-economical integration of the 
community.
34,35
 After migration, foreign born people 
are exposed to a series of additional factors that have 
been associated with an increasing risk of acquiring or 
reactivating TB infection such as poverty, stressful 
living condition, material deprivation, social 
inequalities, unemployment, fewer educational 
opportunities, overcrowded housing, malnutrition, 
substance abuse, and limited access to health care.
36
  
TB in migrants may occur as a consequence of a 
reactivation of a LTBI acquired in the country of 
origin, but also because of a new infection acquired in 
the host country after resettlement or during travel in 
the country of origin. Molecular epidemiology 
studies have helped to understand the relevance of 
 
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
Table 2. Number and portion of cases of active tuberculosis in 
foreign origin people diagnosed in countries of the European 
Economic Area and selected low TB incidence countries.5,6,39,93,94 
Country 
Number of TB cases 
diagnosed in foreign 
origin subjects 
Portion of TB cases 
diagnosed in foreign 
origin subjects 
European 
Economic Area* 
  
Austria  326 47.5% 
Belgium  544 52.1% 
Bulgaria  9 0.4% 
Cyprus  45 83.3% 
Czech Republic  112 18.7% 
Denmark  235 61.7% 
Estonia 48 14.1% 
Finland  79 24.3% 
France  2,456 49.7% 
Germany  2,025 46.9% 
Greece  216 44.2% 
Hungary  27 1.9% 
Ireland  179 42.1% 
Italy 1,677 47.6% 
Latvia  59 6.7% 
Lithuania  44 2.3% 
Luxemburg 21 80.8% 
Malta 28 84.8% 
Netherland 710 70.5% 
Poland 38 0.4% 
Portugal 385 15.2% 
Romania 50 0.3% 
Slovakia 3 0.8% 
Slovenia 57 29.7% 
Spain 2,138 31.6% 
Sweden 524 89.4% 
United Kingdom 6,287 70.1% 
Iceland 7 77.8% 
Liechtenstain - - 
Norway 317 87.8% 
United States* 6,510 62% 
Canada° ~1,040 66% 
Australia^ 1,141 88% 
New Zealand* 227 75.4% 
*Data referred to 2011 ° Data referred to 2010; ^ Data referred to 
2009 
LTBI reactivation in the pathogenesis of TB in 
migrants. In these studies, clustered cases (defined as 
two or more cases with clonally related TB strains) are 
assumed to belong to a chain of recent transmission, 
while cases whose M. tuberculosis isolates display 
unique patterns are regarded as sporadic and assumed 
to be caused by reactivation.
35
 According to the 
different studies, 10%-45% of TB cases diagnosed in 
foreign-born patients are clustered,
35,37,38
 this means 
that a relevant proportion of active TB cases is 
probably caused in immigrants by new infection 
acquired after migration, even if the majority of cases 
are due to LTBI reactivation acquired before migration. 
 As well known a considerable portion (23-53%) of 
TB cases in migrants is diagnosed in the first years (2-
4) after resettlement in the host country.
6,39-41
 However, 
the reasons for this phenomenon are not completely 
clear. Some authors suggest that the stressful and 
socioeconomically disadvantaged living conditions in 
the first years after migration could contribute to the 
reactivation of TB early after arrival.
36
 However, the 
risk of TB in migrants was found to persist for their life 
time.
42
 For example, in one study, one third of TB 
cases in Australia migrants were diagnosed 10 years 
after arrival, and this interval was larger when 
considering European migrants only.
43
 
An increased risk of TB is still present in second 
generation migrants in which a link to endemic 
countries persists after migration through social 
networks or travel in the country of origin of their 
ethnic minority group.
44,45
 In United Kingdom (UK), 
for example, the highest incidence rates in UK born 
subjects are in ethnic minority groups.
46
 The role of 
travel to visit friends and relatives on the risk of TB 
infection during an international travel is not exactly 
known. However the risk for an international traveler 
approximates the risk of transmission in the local 
population of the country of destination,
47
 and it is 
associated with duration of travel.
48
 Among travelers, 
immigrant visiting friends and relatives, especially 
children, are likely to represent a group at higher risk, 
perhaps due to their closer contact with the local 
population as shown by several studies that report an 
association between TST positivity and return to the 
country of origin.
49
 
 
TB Diagnosis and Management in Tropical Areas. 
The most common symptom of pulmonary TB is a 
productive cough for more than 2 weeks, which may be 
accompanied by other respiratory symptoms (shortness 
of breath, chest pains, hemoptysis) and/or 
constitutional symptoms (loss of appetite, weight loss, 
fever, night sweats, and fatigue).
50
 The presence of 
those symptoms are enough to met the definition of 
suspected TB case according to the World Health 
Organization (WHO).
50
 
For a patient living in a remote tropical village that 
has cough for more than 2 weeks, the way to achieve 
the correct diagnosis of TB, to start anti-tubercular 
treatment and to complete it successfully may be very 
long and full of hurdles. According to a systematic 
review, in resource limited countries the average 
patient delay (time from the onset of symptoms until 
the patient see the first health care practices) and 
average health system delay (time from the first health 
care seeking for diagnosis until the diagnosis made) are 
31.7 days and 28.5 days, respectively.
51
 
Low educational level, low awareness and 
knowledge about TB and sociopsychological barriers, 
gender inequalities, are the first bottlenecks for the 
initial health access.
52
 Believing TB incurable or 
caused by evil spirit, possible social exclusion 
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following the diagnosis of TB (stigma), fear of 
revealing HIV status to neighbors, since TB is closely 
related to HIV in tropical areas, are some the factors 
conditioning health seeking behaviors and the 
diagnostic delay in tropical countries.
52
 
Rural residence and other geographical barriers are 
further limiting factors in the diagnostic path. Ideally a 
health facility able to start the clinical management of a 
suspected TB case should be within 1-day walking 
distance as many patients have limited access to 
motorized vehicles.
52
 However, in 2011 the WHO 
estimates that only 15 of the 22 high TB burden 
countries met the target of having 1 microscopy centre 
per 100,000 population and 17 of the 36 countries with 
a high burden of TB and multidrug-resistant (MDR) 
TB have the recommended capacity of 1 laboratory to 
perform culture and drug susceptibility test (DST) per 
5 million population.
2
 
Initial visit to a governmental low-level healthcare 
facility, initial visit to traditional or unqualified 
practitioner or even a visit to a private practitioner are 
factors associated with further diagnostic delay.
52
 The 
delay in diagnosis from this point forward reflects a 
lack of effective diagnostic tools and follow-up 
routines since a correct diagnosis requires both good 
training and available diagnostic facilities.
52
 Table 3 
reports the list of the most important factors associated 
with diagnostic delay according to a systematic 
review.
52
 
Diagnosis of TB is a challenge not only in tropical 
countries, but anywhere resources are limited. 
Conventional microbiological methodology such as 
direct microscopy and culture, when available, have 
intrinsic limitation that have constrained TB care and 
control up to now.
2
 Smear microscopy has a low 
sensitivity (about 64%),
53
 which is even lower in HIV 
positive patients
54
 and in children.
55
 Culture is 
considered the gold standard but requires some weeks 
to give a positive result and even new liquid culture 
techniques, which are more sensitive and allow a faster 
grown of mycobacteria, are seldom available in 
resource-constrained settings largely because of cost.
56
 
Radiology has an important role in the diagnosis of TB 
but the equipment is expensive to obtain, maintain, 
operate and experienced radiologist are required in 
order to interpret the often non-specific radiological 
signs of TB.
3
 Few years ago, the situation of 
radiological manpower and facilities in sub-Saharan 
Africa was reported to show a desperate shortage of 
radiologists, radiographers and equipment, with most 
of services located in the capital with few at rural 
hospital and CT scanners or high resolution ultrasound 
machines available only in 40% of these countries.
57
 
In view of the paucity of diagnostic tools available, 
the  challenge  of  TB  diagnosis  in  the tropics may be 
Table 3. Risk factors for TB diagnostic delay (adapted from Storla 
DG et al).52 
Coexistence of chronic cough and/or other lung diseases 
Negative sputum smear 
Extrapulmonary TB  
Rural residence  
Low access to healthcare  
(geographical or socio-psychological barriers) 
Initial visit to government low-level healthcare facility 
Initial visit to traditional or unqualified practitioner 
Initial visit to private practitioner  
Initial visit to tertiary-level services/hospital  
Old age  
Poverty  
Female sex  
Alcoholism or substance abuse  
History of immigration  
Low educational level and/ 
or low awareness and knowledge about TB 
Generally poor health  
Smoking  
Coexistence of sexually transmitted diseases 
Less severe and indifferent symptoms  
No hemoptysis  
Married 
Single  
Large family size 
Farmer 
White (vs. aboriginal)  
Muslim 
Belonging to an indigenous group  
No insurance  
Beliefs about TB (not curable, caused by evil spirits, etc.)  
Stigma 
Self-treatment 
The study by Storla DG et al. was a systematic review that includes 
58 articles in the final analysis. Thirty eight studies (65%) were 
carried out in countries with incidence >40 per 100,000 population 
(the majority of which tropical), while 20 studies (35%) were 
carried out in non-tropical lower incidence countries. 
"HIV" and "Initial visit to tertiary-level services/hospital" have 
been removed from the original table because they were negatively 
associated with diagnostic delay according to the majority of the 
studies. 
related to problems of differential diagnosis. In the 
tropics, pulmonary TB must be distinguished from 
other rare endemic and ubiquitous conditions such 
bacterial pneumonia, histoplasmosis, 
paracoccidioidomycosis, coccidioidomycosis, 
melioidosis, actinomycosis, paragonimiasis, 
echinococcosis, nocardial and aspergillus mycetoma, 
dirofilariosis, neoplasm, sarcoidosis,
58,59
 which could 
be a hard task, given the limited diagnostic resources 
available. 
Hopefully, the recent availability of new rapid tests 
could revolutionize TB care in endemic and tropical 
countries. The new test Xpert MTB/RIF, which has 
been endorsed by WHO in December 2010, is a 
cartridge-based automated diagnostic test that has three 
main advantages if compared with older tests: 1) it 
enables simultaneous detection of M. tuberculosis 
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complex and rifampicin-resistant associated genotype; 
2) provides accurate results in less than two hours so 
that patients can be offered proper treatment on the 
same day; 3) has minimal bio-safety requirements, 
training, and can be housed in non-conventional 
laboratories.
60
 According to a meta-analysis, the pooled 
sensitivity was 98.7% for pulmonary sputum positive 
TB and 75% for sputum negative TB with an overall 
specificity of 98.4%, while the sensitivity on non-
respiratory clinical samples resulted to be 80.4%.
61, 62
 
Xpert MTB/RIF showed dramatic cut of the time 
needed to start treatment, especially in smear negative 
cases, and to obtain rifampicin susceptibility result.
 63
 
With the introduction of Xpert MTB/RIF, there has 
been also an increase of the number of 
microbiologically confirmed TB in children,
62
 and an 
increase of the number of pulmonary TB cases detected 
in HIV positive patients when compared with 
microscopy.
62 
Between its endorsement by WHO and 
the end of June 2012, 1.1 million test cartridges were 
procured in 67 (46%) of the 145 countries eligible to 
purchase them at initial concessional prices (9.98 $ per 
test from August 2012).
62
 Currently, WHO strongly 
recommends the use of Xpert MTB/RIF for use, as the 
primary diagnostic test, in individuals suspected of 
having MDR or HIV-associated TB and in testing 
cerebrospinal fluid specimens from patients presumed 
to have TB meningitis; furthermore, WHO  provides 
“conditional recommendations” for its use in other 
settings.
64
 However, several weakness of this new tool 
have already been highlighted, including elevated cost 
of the platform (17,000$), the sophisticated hardware 
needing calibration and maintenance, need of 
continuous electrical power supply and air 
conditioning, short shelf life of cartridges needing good 
procurement system, need for cartridges storage at 2-
28°C and system for disposal after use.
62
 Concerning 
other relatively recent diagnostic tools such as 
interferon gamma release assays (IGRA) and 
serological test for TB, WHO recommended against 
their use in middle and low income countries for the 
diagnosis of both active and LTBI.
2
 
Directly Observed Treatment (DOT) of TB reduces 
TB related death, disability and transmission, and it is 
highly cost-effective intervention even in the lowest 
income countries.
2 
Treatment of a drug-sensitive TB, 
case, takes 6 months, while treatment for MDR TB 
case takes 18-20 months according to the WHO 
recommendations.
2 
The target of 85% of treatment 
success for new TB cases has been achieved at global 
level, but it is still under the goal threshold in African 
(73%), Americas (74%) and European Regions (74%), 
with the lowest rate (53%, possibly underestimated) 
reached by South Africa.
2 
 
Concerning patients with MDR-TB, that represent a 
growing portion of cases, only 44% to 58% completed 
treatment successfully according to different Regions.
2 
In Africa, 19% of patients with MDR-TB is not able to 
complete the treatment because of death.
2
 
TB and HIV are strictly related, and the 
management of the two conditions must go hand in 
hand. To date only 40% of patients with TB are tested 
for HIV, with the African Region performing better 
than all other regions (69%).
2 
However only 56% of 
people eligible for antiretroviral therapy is receiving it 
in Africa.
65
 The assessment of the HIV status in a 
patient with TB is essential since the timely start of 
antiretroviral therapy has been demonstrated to reduce 
significantly the mortality of the patient.
66-68
 Treatment 
success of TB is hampered by several problems that 
may be amplified especially in tropical areas, such as 
problematic access to health care facilities, poor 
adherence to treatment, availability of quality drugs, 
high rate of MDR cases, and HIV co-infection. 
Treatment default implies persistence of infection 
source, increased mortality, increased relapse rates and 
increased risk of the development of resistant strains.  
In different case control studies, frequently 
identified risk factors associated with a default of the 
patients under TB treatment in tropical areas were 
inadequate knowledge on TB,
69,70
 illiteracy or low 
education level,
70,71
 herbal medication use,
69
 low 
income,
69
 alcohol abuse,
69-71
 HIV co-infection,
69,71
 male 
gender
69
 poor patient-provider interaction,
70
 side 
effects to anti TB drugs.
70
 
The erratic supply of drugs that may affect some 
areas is another relevant problem. A survey carried out 
in Ethiopia in 2008 showed that the first line drugs for 
TB treatment were not available in about 20% of 48 
health facilities that were supposed to have.
72
 Doctors 
without Borders recently reported a drug supply crisis 
in Mthatha (South Africa) started in 2013.
73
 During a 
survey done in May 2013 in the area, still 40% of 
facilities suffered stock-outs of antiretroviral drugs 
and/or TB drugs with a median duration for reported 
stock-outs of 45 days.
73
 
 
TB Diagnosis and Management in Immigrants. The 
access to health system, including TB diagnostic and 
treatment services is lower in migrant populations 
compared to native subjects. Migrants have a longer 
patient diagnostic delay for TB (defined as the time 
elapsed from the onset of symptoms and the first 
medical consultation), while natives have a longer 
health care diagnostic delay (defined as the time 
elapsed between the first medical consultation and the 
initiation of treatment).
74,75
 The increased patient delay 
is possibly due to a combination of reasons that hinder 
migrants of using the available TB services. Among 
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those factors, there are language barriers, possible lack 
of medical insurance, fear of deportation (for illegal 
migrants) or discontinuation of their employment
74,75
 
and competing socio-economic priorities may prevail 
over health issues. Even if in most of countries TB 
diagnosis and treatment are provided for free at 
government health facilities to all migrants, including 
illegal migrants, additional costs of transport and the 
time needed to perform medical consultations may 
represent significant obstacles for access to health 
system for migrants on low wages.
76
 The longer health 
care diagnostic delay in native subjects can be 
explained by the lower TB incidence among native 
subjects in low endemic countries, that leads 
physicians to reduce their index of suspicion regarding 
the possibility of TB diagnosis and ordering other tests 
rather than TB-diagnostic tests.
74,75
 
TB treatment in migrant populations can be 
challenging due to lower adherence to treatment.
77-79
 
According to a recent study, loss to follow-up in TB 
cases in UK appears to occur primarily in young male 
adults and in subjects born outside the UK, particularly 
those who migrated within the 2 years prior to 
diagnosis.
77
 Moreover, this study showed that lost to 
follow-up patients were more frequently infected with 
a resistant M. tuberculosis strain compared to patients 
who completed or were still on treatment (11% vs. 
7.4%), highlighting the vicious circle among poor 
compliance to treatment and resistance to 
antitubercular drugs.
77
 Higher therapeutic abandonment 
has been recently found also in foreign born patients if 
compared to natives in Granada (Spain)
79
 and in 
Chinese internal migrants if compared to permanent 
residents.
78
 
Another challenging issue in the management of TB 
in migrants, in low endemic countries, is the high 
frequency of MDR-TB in this population if compared 
to natives (Table 4). The majority of European and 
other low prevalence countries, excluding some of the 
high priority countries in the WHO European Region 
(such as Latvia, Lithuania, Bulgaria and Estonia), 
report higher prevalence of MDR-TB cases in migrants 
if compared to the native population.
80
 This is probably 
due to the high prevalence of MDR-TB in migrants 
countries of origin and possibly to the low compliance 
to treatment that characterizes migrants and leads to 
acquire drug resistance. 
Given the epidemiological importance of migrant 
subjects in determining the epidemiology of TB in 
industrialized countries, many of those countries 
implemented different control measures for TB, 
including mass screening programs. The rationale of 
these programs is the early detection and treatment of 
active and then contagious TB cases, in order to 
prevent  M. tuberculosis  transmission  within  the  host 
 
Table 4. Prevalence of Multi Drug Resistance in native and foreign 
origin subjects diagnosed with tuberculosis in countries of the 
European Economic Area and selected low TB incidence 
countries.5,6,39,93,94 
Country MDR prevalence in subject with TB (%) 
 Native Foreign origin 
European 
Economic Area* 
  
Austria  0 8.9 
Belgium  0 3.7 
Bulgaria  7.5 0 
Cyprus  0 3 
Czech Republic  0.6 6.2 
Denmark  0 1.8 
Estonia 30.3 25.8 
Finland  1.3 4.4 
France  - - 
Germany  0.6 3.4 
Greece  0 5.6 
Hungary  1.3 10 
Ireland  0 1.7 
Italy 1.4 4.2 
Latvia  14.9 13.3 
Lithuania  20.9 29.4 
Luxemburg 0 13.3 
Malta 0 0 
Netherland 0 2.8 
Poland 0.8 3.8 
Portugal 1.1 5.4 
Romania 8.8 14.3 
Slovakia 1.6 0 
Slovenia 0 0 
Spain - - 
Sweden 0 3.9 
United Kingdom 0.3 2.1 
Iceland - 0 
Liechtenstain - - 
Norway 0 1.7 
United States*# 0.6 1.7 
Canada - - 
Australia - - 
New Zealand* 0 1.1 
Footnotes: *Data referred to 2011; # Data referred to cases without 
previous diagnosis of TB. 
 
country.
81
 Indeed screening for active TB may decrease 
the period of infectiousness by as much as 33%.
82
 
Secondary benefits of immigration screening are 
reduced transmission of TB in the country of origin and 
during travel.
81
 
A recent survey showed that high-income 
industrialized countries have widely different 
approaches to the screening of migrants arriving in 
their territories.
83
 In the majority (23 of 25, 92%) of 
cases, screening is performed after the arrival, while 
only 36% (9 of 25) and 20% (5 of 25) of countries 
perform also pre-arrival and at-arrival screening 
respectively, according to the different type of 
immigrants.
83
 The majority of countries (25, 86.2%) 
screens for active TB and most commonly (76% of 
cases) the screening is compulsory.
83
 The most 
commonly used tool for screening for active TB in 
Mediterr J Hematol Infect Dis 2014; 6: Open Journal System  
 
adult migrants is a chest radiograph, which is used by 
22 of 25 (88%) industrialized countries alone or in 
combination with clinical examination and less 
commonly, with tuberculin skin test (TST).
83
 However, 
screening protocols based on chest x-ray only are 
unable to detect cases of extrapulmonary TB, which 
represent a not negligible portion of TB cases in 
migrant patients (24% of cases diagnosed in non US 
born patient in US).
84
 Moreover, concerning pulmonary 
TB, chest x-ray shows a sensitivity of 86-97% and a 
specificity of 75-89% according to the different criteria 
used for imaging interpretation.
85
 The median yield of 
screening for TB disease (portion of patients with 
active TB among those screened) has been found quite 
low (0.18%) in the EEA.
86
 
Only 16 of 29 (55.2%) countries, inquired in the 
above survey, screens for LTBI by using TST in 68.8% 
of cases or TST plus a confirmatory IGRA in 25% or 
an IGRA alone in 18.8%.
83
 Some authors strongly 
support the implementation of screening for LTBI 
based on the evidence that the majority of active TB 
cases, diagnosed in migrants, are due to a LTBI 
reactivation acquired in the country of origin
38
 and on 
the findings of cost-effectiveness analysis.
87,88
 
According to a cost-effectiveness study, the most 
suitable strategy would be to screen with an IGRA (in 
particular QuantiFERON-TB Gold In-Tube. Carnegie, 
Cellestis, Australia) test all migrants coming in UK 
from countries with an incidence of more than 250 
cases per 100,000 (incremental cost-effectiveness ratio 
[ICER] of £ 21,565 per prevented case of TB) without 
port of arrival chest x-ray.
88
 However these results are 
opposite to those of a previous study done in Canada 
that found chest radiograph the most and Quantiferon 
the least cost-effective strategy to screen migrants.
89
 
The discordance of the findings are probably explained 
by the different assumptions done in the models such 
as high rates of acceptance and completion of 
chemoprophylaxis assumed in the English study and 
low prevalence of latent infection in new immigrants 
assumed in the Canadian study. 
While the attention of the different governmental 
programs and several scientists seems to focus on mass 
screening programs for active TB and/or LTBI, this 
kind of interventions should not represent a stand-alone 
intervention, but a component of a wider approach.
86
 
The six points proposed by the STOP TB strategy 
(Table 5),
80
 which address the activities to deal with 
TB at global level, could be a useful paradigm for 
drawing a more comprehensive approach for TB 
control in migrant populations.  
Table 5: The six components of the STOP TB strategy.80 
1) Pursue high-quality DOTS expansion and enhancement 
2) Address TB-HIV, MDR-TB, and the needs of poor and 
vulnerable populations 
3) Contribute to health system strengthening based on primary 
health care 
4) Engage all care providers 
5) Empower people with TB, and communities through partnership 
6) Enable and promote research 
 
Implementing DOT in low endemic areas or newer 
socially and culturally acceptable programs to sustain 
treatment adherence, address MDR-TB, contributing to 
health systems strengthening with the presence of peer 
educators and culturally-oriented health staff, engaging 
all care providers including members of Non 
Governmental Organizations and voluntary 
associations, empowering migrants communities and 
promoting research to find new possible operational 
solutions and tools for TB care and prevention could 
likely be of benefit for future TB control programs in 
migrants.
90
 
In conclusion TB care should be offered and 
integrated with other healthcare activities within the 
context of a holistic approach to ensure the health and 
wellbeing of new entrant migrants.
76,91,92
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